AMAM लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (7 Mar 2024 @ 02:30):

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform...

Stats
आज की मात्रा	1.42M
औसत मात्रा	1.94M
बाजार मूल्य	1.77B
EPS	$0 ( 2024-04-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	66.67
ATR14	$0.381 (1.36%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-11	O'connor Daniel J.	Buy	750 000	Common Stock
2023-10-27	O'connor Daniel J.	Sell	50 012	Common Stock
2023-10-23	Cormorant Asset Management, Lp	Buy	1 307 311	Common Stock
2023-09-18	Cormorant Asset Management, Lp	Buy	751 233	Ordinary Shares
2023-09-15	Cormorant Asset Management, Lp	Buy	1 401 505	Ordinary Shares

INSIDER POWER
64.48
Last 64 transactions
Buy: 36 374 710 \| Sell: 11 079 608

मात्रा सहसंबंध

लंबा: 0.14 (neutral)

छोटा: -0.26 (neutral)

Signal:(82.204) Neutral

Ambrx Biopharma Inc. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
KDMN	0.991
KR	0.962
DY	0.959
NMM	0.958
VST	0.954
TGT	0.954
ARIS	0.952
TRGP	0.952
EME	0.95
SNDA	0.95

10 सबसे अधिक नकारात्मक सहसंबंध
EVC	-0.963
SSU	-0.963
SQZ	-0.961
FRC	-0.956
AVYA	-0.953
DAVA	-0.952
DTLA-P	-0.951
LITB	-0.946
NGE	-0.944
FRC-PN	-0.94

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Ambrx Biopharma Inc. सहसंबंध - मुद्रा/वस्त्र

0.26
( neutral )

0.46
( neutral )

-0.75
( moderate negative )

-0.19
( neutral )

0.57
( weak )

-0.29
( neutral )

Ambrx Biopharma Inc. वित्तीय

Annual	2022
राजस्व:	$7.40M
सकल लाभ:	$7.40M (100.00 %)
EPS:	$-2.02

FY	2022
राजस्व:	$7.40M
सकल लाभ:	$7.40M (100.00 %)
EPS:	$-2.02

FY	2021
राजस्व:	$7.46M
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-3.36

FY	2020
राजस्व:	$13.67M
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-0.439

Financial Reports:

No articles found.

Ambrx Biopharma Inc.

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.